CL2018000032A1 - Método para mejorar la solubilidad acuosa de drogas insolubles o ligeramente solubles en el agua - Google Patents
Método para mejorar la solubilidad acuosa de drogas insolubles o ligeramente solubles en el aguaInfo
- Publication number
- CL2018000032A1 CL2018000032A1 CL2018000032A CL2018000032A CL2018000032A1 CL 2018000032 A1 CL2018000032 A1 CL 2018000032A1 CL 2018000032 A CL2018000032 A CL 2018000032A CL 2018000032 A CL2018000032 A CL 2018000032A CL 2018000032 A1 CL2018000032 A1 CL 2018000032A1
- Authority
- CL
- Chile
- Prior art keywords
- water
- solvent
- insoluble
- organic
- slightly soluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0291—Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
Abstract
UUN MÉTODO PARA AUMENTAR LA SOLUBILIDAD DE UN COMPUESTO ORGÁNICO HIDROFÓBICO INSOLUBLE EN AGUA O LIGERAMENTE SOLUBLE EN AGUA EN UN SOLVENTE ACUOSO QUE COMPRENDE AÑADIR UN COMPONENTE DE SAPONINA SELECCIONADO DEL GRUPO QUE CONSISTE EN ESCINA, GLICIRRICINA Y EXTRACTO DE QUILLAJA SAPONARIA AL SOLVENTE ACUOSO EN UNA CANTIDAD SUFICIENTE PARA DESENCADENAR LA FORMACIÓN DE MICELAS, EN EL QUE EN UNA PRIMERA ETAPA EL COMPUESTO ORGÁNICO HIDRÓFOBO SE DISUELVE PREVIAMENTE EN UN SOLVENTE ORGÁNICO, DESPUÉS DE LO CUAL, EN UNA SEGUNDA ETAPA, EL SOLVENTE ORGÁNICO QUE COMPRENDE EL COMPUESTO DISUELTO PREVIAMENTE SE MEZCLA CON EL SOLVENTE ACUOSO; CON LO CUAL AL MENOS UNA PARTE DEL COMPUESTO ORGÁNICO HIDROFÓBICO INSOLUBLE O LIGERAMENTE SOLUBLE SE SOLUBILIZA Y SE DISUELVE EN EL SOLVENTE ACUOSO, PRODUCIENDO UNA COMPOSICIÓN ACUOSA QUE TIENE UNA CONCENTRACIÓN INCREMENTADA DE DICHO COMPUESTO ORGÁNICO DISUELTO EN ELLA. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS O COSMÉTICAS QUE COMPRENDEN UN COMPUESTO ORGÁNICO INSOLUBLE EN AGUA O LIGERAMENTE SOLUBLE EN AGUA DISUELTO EN UN SOLVENTE ACUOSO A CONCENTRACIONES SUSTANCIALMENTE INCREMENTADAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201514801578A | 2015-07-16 | 2015-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000032A1 true CL2018000032A1 (es) | 2018-11-16 |
Family
ID=56418519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000032A CL2018000032A1 (es) | 2015-07-16 | 2018-01-05 | Método para mejorar la solubilidad acuosa de drogas insolubles o ligeramente solubles en el agua |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP3324933B1 (es) |
| JP (1) | JP6836825B2 (es) |
| KR (1) | KR102615005B1 (es) |
| CN (1) | CN107847440B (es) |
| AU (1) | AU2016293125B2 (es) |
| CA (1) | CA2992376C (es) |
| CL (1) | CL2018000032A1 (es) |
| CO (1) | CO2018001460A2 (es) |
| CY (1) | CY1124322T1 (es) |
| DK (1) | DK3324933T3 (es) |
| EA (1) | EA036233B1 (es) |
| ES (1) | ES2844581T3 (es) |
| HR (1) | HRP20210333T1 (es) |
| HU (1) | HUE053116T2 (es) |
| IL (1) | IL256882B (es) |
| LT (1) | LT3324933T (es) |
| MA (1) | MA42472B1 (es) |
| MX (1) | MX379341B (es) |
| MY (1) | MY196065A (es) |
| NZ (1) | NZ738592A (es) |
| PH (1) | PH12018500042A1 (es) |
| PL (1) | PL3324933T3 (es) |
| PT (1) | PT3324933T (es) |
| RS (1) | RS61561B1 (es) |
| SA (1) | SA518390688B1 (es) |
| SI (1) | SI3324933T1 (es) |
| UA (1) | UA123312C2 (es) |
| WO (1) | WO2017009480A1 (es) |
| ZA (1) | ZA201708594B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108143713A (zh) * | 2018-01-04 | 2018-06-12 | 南方医科大学南方医院 | 一种增加羟喜树碱溶解度的方法 |
| US12377046B1 (en) | 2019-04-24 | 2025-08-05 | Wellomics LLC | Delivery system matrices |
| CN110074385B (zh) * | 2019-05-21 | 2022-05-31 | 绥化市蓝源生物工程有限公司 | 一种生物碱溶解纳他霉素的生物溶剂及其应用 |
| KR20220022829A (ko) * | 2020-08-19 | 2022-02-28 | 주식회사 모든바이오 | 글리시리진 및 수용성 약물을 포함하는 나노 입자, 이를 포함하는 약제학적 조성물 및 이들의 제조 방법 |
| CN114588118B (zh) * | 2022-01-25 | 2023-05-23 | 武汉爱民制药股份有限公司 | 一种注射用七叶皂苷钠复方制剂 |
| KR102922176B1 (ko) * | 2022-07-08 | 2026-02-04 | 한국생산기술연구원 | 소수성 약물 전달을 위한 금-히알루론산 나노입자의 제조방법 |
| EP4431082A1 (en) * | 2023-03-13 | 2024-09-18 | Marinomed Biotech AG | Aqueous composition comprising budesonide |
| EP4516289A1 (en) | 2023-08-30 | 2025-03-05 | SPH Sine Pharmaceutical Laboratories Co., Ltd | Antiviral nasal spray comprising favipiravir |
| CN117562911B (zh) * | 2023-12-07 | 2024-06-04 | 海南医学院 | 化合物tigloside在制备治疗和/或预防骨关节炎药物中的用途 |
| WO2025133675A1 (en) * | 2023-12-20 | 2025-06-26 | Melikoglu, Ahmet | Method for producing nasal formulation comprising aescin and rutin |
| EP4696300A1 (en) | 2024-08-14 | 2026-02-18 | Marinomed Biotech AG | Aqueous composition comprising fluticasone |
| KR102907892B1 (ko) * | 2025-01-09 | 2026-01-12 | 주식회사 한바이오 | 가용성을 높인 피레스로이드계의 보건용 스프레이 살충제 제조방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1119957A (en) | 1979-12-04 | 1982-03-16 | Martin Whitefield | Steroid compositions |
| US4782047A (en) | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
| US4868170A (en) | 1987-11-13 | 1989-09-19 | E. R. Squibb & Sons, Inc. | Steriod lotion formulation |
| JPH1025255A (ja) * | 1996-07-11 | 1998-01-27 | Taisho Pharmaceut Co Ltd | 溶解性の改善された難溶性薬剤 |
| FR2799369B1 (fr) | 1999-10-08 | 2001-12-21 | Oreal | Association d'escine et de sulfate de dextran et son utilisation |
| US7125564B2 (en) | 2001-02-16 | 2006-10-24 | Lavipharm Laboratories, Inc. | Water soluble and palatable complexes |
| JP4000283B2 (ja) * | 2002-08-07 | 2007-10-31 | 丸善製薬株式会社 | 甘草油性抽出物の可溶化組成物、並びに飲料、液状調味料、化粧品及び医薬部外品 |
| US7897587B2 (en) | 2004-09-03 | 2011-03-01 | Nycomed Us Inc. | Topical dermatological formulations and use thereof |
| JP5128801B2 (ja) * | 2006-10-16 | 2013-01-23 | フロイント産業株式会社 | 高水分散性粉末とその製造方法 |
| JP6265624B2 (ja) * | 2012-05-11 | 2018-01-24 | ロート製薬株式会社 | ルリコナゾール含有外用医薬組成物 |
| US9907846B2 (en) * | 2013-04-01 | 2018-03-06 | Mx Adjuvac Ab | Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions |
| CN103271891B (zh) * | 2013-04-28 | 2016-01-06 | 福建南方制药股份有限公司 | 人参皂苷纳米胶束及其制备方法、应用和药物组合物 |
| CN103520081B (zh) * | 2013-09-27 | 2015-10-28 | 无限极（中国）有限公司 | 一种调节皮肤免疫力、延缓皮肤老化的外用护肤品 |
-
2016
- 2016-07-15 SI SI201631114T patent/SI3324933T1/sl unknown
- 2016-07-15 MX MX2018000286A patent/MX379341B/es unknown
- 2016-07-15 EA EA201890194A patent/EA036233B1/ru unknown
- 2016-07-15 DK DK16739477.4T patent/DK3324933T3/da active
- 2016-07-15 MY MYPI2017704929A patent/MY196065A/en unknown
- 2016-07-15 HR HRP20210333TT patent/HRP20210333T1/hr unknown
- 2016-07-15 PT PT167394774T patent/PT3324933T/pt unknown
- 2016-07-15 KR KR1020187004268A patent/KR102615005B1/ko active Active
- 2016-07-15 NZ NZ738592A patent/NZ738592A/en unknown
- 2016-07-15 PL PL16739477T patent/PL3324933T3/pl unknown
- 2016-07-15 CN CN201680039722.5A patent/CN107847440B/zh active Active
- 2016-07-15 ES ES16739477T patent/ES2844581T3/es active Active
- 2016-07-15 HU HUE16739477A patent/HUE053116T2/hu unknown
- 2016-07-15 WO PCT/EP2016/066999 patent/WO2017009480A1/en not_active Ceased
- 2016-07-15 AU AU2016293125A patent/AU2016293125B2/en active Active
- 2016-07-15 EP EP16739477.4A patent/EP3324933B1/en active Active
- 2016-07-15 CA CA2992376A patent/CA2992376C/en active Active
- 2016-07-15 UA UAA201712614A patent/UA123312C2/uk unknown
- 2016-07-15 LT LTEP16739477.4T patent/LT3324933T/lt unknown
- 2016-07-15 JP JP2017566080A patent/JP6836825B2/ja active Active
- 2016-07-15 RS RS20210293A patent/RS61561B1/sr unknown
- 2016-07-15 MA MA42472A patent/MA42472B1/fr unknown
-
2017
- 2017-12-18 ZA ZA2017/08594A patent/ZA201708594B/en unknown
-
2018
- 2018-01-03 SA SA518390688A patent/SA518390688B1/ar unknown
- 2018-01-04 PH PH12018500042A patent/PH12018500042A1/en unknown
- 2018-01-05 CL CL2018000032A patent/CL2018000032A1/es unknown
- 2018-01-11 IL IL256882A patent/IL256882B/en unknown
- 2018-02-14 CO CONC2018/0001460A patent/CO2018001460A2/es unknown
-
2021
- 2021-03-12 CY CY20211100218T patent/CY1124322T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000032A1 (es) | Método para mejorar la solubilidad acuosa de drogas insolubles o ligeramente solubles en el agua | |
| MX2018011881A (es) | Sistema de administracion. | |
| MX2022003572A (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| CL2019000266A1 (es) | Composición de cannabis. | |
| BR112014029762A2 (pt) | composição contendo n-metil-n-acilglucamina | |
| MX2016004035A (es) | Formulaciones de espiro-isoxazolina de accion prolongada. | |
| BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
| MX2018000016A (es) | Composiciones farmaceuticas liofilizadas. | |
| EA201891783A1 (ru) | Композиция для растворения аморфных дитиазинов и способ ее применения | |
| CO2019003876A2 (es) | Formulación farmacéutica parenteral que contiene ácido carglúmico | |
| MX2015009701A (es) | Proceso de obtencion de nonoparticulas biopolimericas conteniendo aceite y extractos de azadirachta indica a, juss (neem), nanoparticulas biopolimericas y microparticulas en polvo. | |
| MX2022012075A (es) | Formulaciones de farmacos de moleculas peque?as resistentes a precipitacion. | |
| MX2017009482A (es) | Formulación farmacéutica. | |
| CO2019005156A2 (es) | Composición para el tratamiento y/o prevención de la enfermedad fúngica sigatoka negra en los cultivos de banana | |
| BR112018067918A2 (pt) | formulações livres de solvente de substâncias ativas com baixo ponto de fusão | |
| CL2019001806A1 (es) | Nanoemulsiones cargadas con curcumina, método de preparaciòn, y método de tratamiento preventivo que las usa | |
| CL2019002985A1 (es) | Método para preparar una composición con un bajo contenido de oxígeno disuelto, que comprende paracetamol, y opcionalmente uno o más aine, y una composición obtenida de la misma. | |
| PE20140035A1 (es) | Composicion inyectable que comprende un antiinflamatorio no esteroideo y un antibiotico | |
| EA201691825A1 (ru) | Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта) | |
| BR112019023074A2 (pt) | composição contendo ciclodextrina e bussulfano | |
| BR112016028412A2 (pt) | composição farmacêutica, método para a preparação de uma composição farmacêutica, e kit | |
| MX383557B (es) | Formulaciones inyectables de paracetamol. | |
| PE20191462A1 (es) | Composicion liquida que contiene pradofloxacina | |
| SV2016005348A (es) | Mã‰todos para tratar infecciones | |
| AR123571A2 (es) | Solución acuosa estéril de agente neuroactivo |